Literature DB >> 29620667

Early plasma monocyte chemoattractant protein 1 predicts the development of sepsis in trauma patients: A prospective observational study.

Yuchang Wang1, Qinxin Liu, Tao Liu, Qiang Zheng, Xi'e Xu, Xinghua Liu, Wei Gao, Zhanfei Li, Xiangjun Bai.   

Abstract

Monocyte chemoattractant protein 1 (MCP-1) is an initiating cytokine of the inflammatory cascade. Extracellular MCP-1 exhibits pro-inflammatory characteristic and plays a central pathogenic role in critical illness. The purpose of the study was to identify the association between plasma MCP-1 levels and the development of sepsis after severe trauma.The plasma levels of MCP-1 in severe trauma patients were measured by a quantitative enzyme-linked immune sorbent assay and the dynamic release patterns were recorded at three time points during seven days post-trauma. The related factors of prognosis were compared between sepsis and non-sepsis groups and analyzed using multivariate logistic regression analysis. We also used receiver operating characteristic (ROC) curves to assess the values of different variables in predicting sepsis.A total of 72 patients who met criteria indicative of severe trauma (72.22% of male; mean age, 49.40 ± 14.29 years) were enrolled. Plasma MCP-1 concentrations significantly increased on post-trauma day 1 and that this increase was significantly correlated with the Injury Severity Score (ISS) and interleukin-6 (IL-6). Multivariate logistic regression analysis showed that early MCP-1, ISS, and IL-6 were independent risk factors for sepsis in severe trauma patients. Incorporation of the early MCP-1 into the ISS can increase the discriminative performance for predicting development of sepsis.Early plasma MCP-1 concentrations can be used to assess the severity of trauma and is correlated with the development of sepsis after severe trauma. The addition of the early MCP-1 levels to the ISS significantly improves its ability to predict development of sepsis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620667      PMCID: PMC5902265          DOI: 10.1097/MD.0000000000010356

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Sepsis and infectious complications are major contributing factors to trauma-related mortality.[ Timely detection and treatment of emerging infections can allow us to take measures for treatment as early as possible, thereby reducing post-trauma mortality and improving patient outcome. Hence, effective identification of severe trauma patients who have the potential to develop life-threatening infectious complications and are at the risk of death is still an urgent problem. Severe trauma can induce exacerbation of systemic inflammation, which often progresses to sepsis leading to a lethal outcome.[ Numerous of evidence has been sought to identify biomarkers to predict patients who are at high-risk of morbidity and mortality. Many biomarkers, such as monocyte human leukocyte antigen-DR(HLA-DR), high mobility group box 1(HMGB1), and interleukin-6 (IL-6), which are involved in systemic inflammation caused by trauma and relate to the severity of injury, have been assessed as potential markers to predict poor prognosis in critical ill patients.[ Unfortunately, all of these biomarkers lack sufficient specificity. Monocyte chemo-attractant protein 1 (MCP-1), also referred to as C-C motif chemokine ligand 2 (CCL2), was discovered originally as one of the key chemokines that regulate migration and infiltration of monocytes/macrophages.[ It is also an important molecule for regulating leukocyte function and mediating various inflammation-promoting biological activities.[ A growing body of work has demonstrated that MCP-1 plays a key pathogenic role in the pathogenesis mechanisms of leading sepsis.[ Therefore, MCP-1 is an interesting candidate biomarker for monitoring patients with severe trauma. However, the changes and significance of MCP-1 in trauma patients have not been well-elucidated. The objective of the present study was to investigate the time course of MCP-1 levels in patients with severe trauma and to determine whether MCP-1 can serve as a biomarker to predict the development of sepsis in trauma patients.

Methods

Study setting, design and patient selection

This prospective study was conducted from October 2016 to March 2017 in the traumatic department of the Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. The study was strictly observational and did not interfere with the decision-making process and clinical management. The protocol for this study was approved by the Ethical and Protocol Review Committee of the Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, and informed consent was obtained from their next of kin. The enrolment criteria consisted of a history of trauma (Injury Severity Score [ISS] ≥16), age between 18 and 80 years, admitted to the hospital within 24 hours after injury. Patients with known pre-existing concomitant acute myocardial infarction, burns, thromboembolic events, and anticoagulant medication were excluded. In addition, patients with inherited or acquired immunodeficiencies and patients receiving immunosuppressive therapy were also excluded from the study. Prophylactic antibiotics were selected and given according to the doctor's experience and related researches.[ For comparison, 10 age-matched and sex-matched healthy volunteers who received an annual physical examination and had no clinical evidence of infection were recruited as controls.

Clinical data collection and evaluation

Demographic characteristics (age and gender), mechanism of injury, ISS, procalcitonin (PCT), IL-6, C-reaction protein (CRP), and days of stay in ICU were collected on admission. Determination of ISS was performed by independent evaluators according to the Abbreviated Injury Scale 2005. In this study, patients were divided into sepsis group and non-sepsis group according to development of sepsis within 28 days post-trauma. According to sepsis-3,[ sepsis was defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction was identified as an acute change in total SOFA (Sequential [Sepsis-related] Organ Failure Assessment) score ≥2 points consequent to the infection. The bloodstream infections were diagnosed according to the isolation of a predominant organism from blood cultures obtained under sterile conditions.

Blood samples

Venous peripheral blood was drawn from the trauma patients on day 1 (within 24 hours), day 3, day 7 after injury. Samples were collected in potassium ethylenediamine tetra-acetic acid (EDTA) coated bottles and centrifuged at 370 × g for 5 minutes. Plasma samples were obtained and stored at −80 °C until further testing. The plasma levels of MCP-1, IL-6, CRP, PCT were tested by commercially available human ELISA kit (GenWay, San Diego, CA), respectively, according to the manufacturer's instruction.

Statistical analysis

Descriptive data were summarized as median (interquartile range), mean ± standard deviation (SD), or frequency (percentage) as appropriate statistical. Statistical analysis was performed by using the SPSS 19.0 statistical software (SPSS, Chicago, IL). Differences between groups were performed by student t-test for continuous variables and by χ test or Fisher exact for categorical variables. Correlations between MCP-1 and ISS, IL-6, CRP, as well as PCT were evaluated using scatterplots and Spearman rank-correlation coefficients. Candidate variables were chosen from univariate analyses and significant univariate variables (P < .15) were included in a backwards multivariate model. Logistic regressions were used as odds ratios (ORs) with 95% CI adjusting for MCP-1 levels, ISS and IL-6. Receiver operating characteristic (ROC) curve analysis was used to evaluate the values of different variables to predict sepsis. Statistical significance was defined as a P < .05.

Results

Study population and baseline characteristics

In the study, a total of 72 patients with serve multiple trauma were recruited and the mean age was 49.40 ± 14.29. 52 patients (72.22%) were male and 20 (27.78%) were female. The mean ISS was 22.63 ± 4.76. Of the patients who were initially evaluated, 9 patients were excluded from the study due to the following reasons: died within 24 hours (n = 4), age younger than 18 years (n = 5). Out of the 72 trauma patients, 45 patients (62.5%) were due to motor vehicle crashes, 9 (12.50%) were caused by falling, and 18 (25.00%) were by other trauma. Thirty-nine patients (54.17%) had brain injury and 45 patients (62.50%) had thoracic injury. Overall, 39 patients (54.17%) developed sepsis, 14 patients (19.44%) died. The length of intensive care unit (ICU) was 7.71 ± 4.04 days (Table 1). Mean SOFA scores were gradually increased and peaked on day 6 in sepsis patients (Supplemental Fig. 1).
Table 1

Demographic and clinical characteristics of the severe trauma patients.

Demographic and clinical characteristics of the severe trauma patients.

Plasma cytokine levels and ISS in trauma patients

The mean plasma MCP-1 levels in trauma patients on post-trauma day 1 were 659.8 (309.9–1010.0) pg/mL, day 3 527.0 (269.2–784.7) pg/mL, day 7 543.8 (280.2–807.4) pg/mL. The overall patterns of plasma concentrations of MCP-1 were increased and peaked on day 1, decreased but remained elevated on day 3 and 5 days (Fig. 1).
Figure 1

Time course of MCP-1 levels after trauma. Mean MCP-1 levels were gradually were increased and peaked on day 1, decreased but remained elevated on day 3 and 5 days. MCP-1: monocyte chemoattractant protein 1.

Time course of MCP-1 levels after trauma. Mean MCP-1 levels were gradually were increased and peaked on day 1, decreased but remained elevated on day 3 and 5 days. MCP-1: monocyte chemoattractant protein 1. There were no significant differences between the sepsis and non-sepsis groups in the plasma levels of PCT (non-sepsis vs sepsis: 7.52 ± 3.39 vs 5.63 ± 2.18pg/mL), CRP (116.76 ± 79.22 vs 98.64 ± 66.47pg/mL). However, significant differences between the sepsis and non-sepsis groups were found for ISS (23.79 ± 4.52 vs 18.24 ± 4.27), MCP-1 (1013.72 ± 572.43 vs 365.18 ± 226.28pg/mL) and IL-6 (80.94 ± 46.42 vs 47.52 ± 26.34pg/mL) (Table 2).
Table 2

ISS and plasma cytokine levels (day 1) in severe trauma patients.

ISS and plasma cytokine levels (day 1) in severe trauma patients.

Early plasma levels of MCP-1 related with sepsis

Patients in the sepsis group had higher ISS (23.79 ± 4.52 vs 18.24 ± 4.27, P < .01) and longer stay in ICU (9.97 ± 3.42 vs 4.26 ± 1.91, P < .01) compared with non-sepsis group. We observed that MCP-1 levels statistically significantly higher on post-trauma day 1 in patients who developed sepsis (1013.45 ± 572.17 pg/ml vs 325.28 ± 148.55 pg/mL, P = .01), but the levels were not significantly different on day 3 (755.3 ± 591.6 pg/mL vs 334.9 ± 156.6 pg/mL, P = .14) and 7 (680.1 ± 643.2 pg/mL vs 329.7 ± 137.8 pg/mL, P = .28) between sepsis group and non-sepsis group (Fig. 2).
Figure 2

Comparison of MCP-1 levels in patients with sepsis and non-sepsis. MCP-1: monocyte chemoattractant protein 1. ∗P < .05.

Comparison of MCP-1 levels in patients with sepsis and non-sepsis. MCP-1: monocyte chemoattractant protein 1. ∗P < .05. The association of plasma MCP-1 levels with the risk of sepsis was assessed after adjusting for potential confounding variables in multivariate analyses. Multivariate analyses showed that MCP-1, ISS, and IL-6 on day 1 were independent risk factors for the development of sepsis in severe trauma patients (1.01 [95% CI, 1.00 ∼ 1.02; P = .02]; 1.64 [95% CI, 1.17 ∼ 2.31; P < .01]; 9.6 [95% CI, 5.72 ∼ 34.8; P = .04] respectively) (Table 3).
Table 3

Multiple logistic regression models of independent risk factorsfor sepsis of severe trauma patients (day 1).

Multiple logistic regression models of independent risk factorsfor sepsis of severe trauma patients (day 1).

Early plasma levels of MCP-1 related with ISS and IL-6

We analyzed the relationship between MCP-1 expression levels and ISS, PCT, CRP, and IL-6 expression levels on day 1. There was no distinct correlation of the MCP-1 expression level with the PCT or CRP (not shown). However, we found that MCP-1 was significantly correlated with the ISS (r = 0.50, P < .01) and IL-6 (r = 0.66, P < .01) (Fig. 3).
Figure 3

The correlations between MCP-1 levels and ISS as well as IL-6 on day 1. MCP-1 was associated with the ISS and IL-6 (r = 0.50, P < .01; and r = 0.66, P < .01, respectively). ISS: Injury Severity Score; MCP-1: monocyte chemoattractant protein 1.

The correlations between MCP-1 levels and ISS as well as IL-6 on day 1. MCP-1 was associated with the ISS and IL-6 (r = 0.50, P < .01; and r = 0.66, P < .01, respectively). ISS: Injury Severity Score; MCP-1: monocyte chemoattractant protein 1.

Predictors of sepsis

In terms of predicting sepsis, AUCs of MCP-1, ISS, IL-6 on day 1 were respectively 0.82 (95% CI 0.71 ∼ 0.93, P < .01), 0.83 (95% CI 0.72 ∼ 0.93, P < .01), and 0.63 (95% CI 0.48 ∼ 0.77, P = .09; respectively). Combined use of the MCP-1 level and ISS score was better than any single indicator alone, with an AUC of 0.87 (95% CI 0.78 ∼ 0.96, P < .01) (Table 4; Fig. 4).
Table 4

Area under the ROC curve for predicting sepsis in trauma patients (day 1).

Figure 4

The ROC curves of MCP-1, ISS, IL-6 and ISS+MCP-1 for predicting sepsis after severe trauma (day 1).

Area under the ROC curve for predicting sepsis in trauma patients (day 1). The ROC curves of MCP-1, ISS, IL-6 and ISS+MCP-1 for predicting sepsis after severe trauma (day 1). Optimum cut-off values for prediction of sepsis were determined on the ROC curve with the maximum Youden index [sensitivity-(1-seecificity)]. The best thresholds of MCP-1, IL-6, ISS for predicting sepsis were 240.7 pg/mL (sensitivity 92.86% and specificity 43.75%), 54.8 pg/mL (sensitivity 73.64% and specificity 54.81%), and 21.5 (sensitivity 75.76% and specificity 88.89%), respectively. Sensitivity and specificity of combining use of MCP-1 and ISS for predicting sepsis were 87.88% and 78.96%, respectively. To evaluate the prognosis of patients with trauma, ISS was better than the MCP-1 and IL-6. However, combining the MCP-1 level and ISS had the best prognostic value.

Discussion

Dysregulation of the host inflammatory response is central to the mortality of patients with sepsis after trauma, involving the activation of numerous immune cells and inflammatory mediators. Despite innovations in therapy, mortality rates for sepsis remain high.[ Therefore, identifying severe trauma patients who are at a high risk of sepsis is crucial for making appropriate and timely interventions to reduce mortality rates. In the absence of specific clinical signs to predict poor prognosis in trauma patients, early biomarkers of immune dysfunction are clearly highly desirable. In our study, we found that level of plasma MCP-1 markedly increased on day 1 after trauma and was a promising biomarker for predicting sepsis in severe trauma patients. MCP-1 plays an important role in various inflammatory diseases, such as experimental allergic encephalitis,[ inflammatory bowel disease,[ allergic asthma,[ and rheumatoid arthritis.[ MCP-1 is secreted by many cell types, including monocytes, endothelial cells, smooth muscle cells, and fibroblasts as an initiating cytokine of the inflammatory cascade.[ Apart from regulating the migration and infiltration of monocytes, memory T lymphocytes, and natural killer (NK) cells, several studies indicate that MCP-1 is also associate with polarized Th2 responses,[ enhancing the secretion of IL-4 by T cells.[ Furthermore, accumulating evidence indicated that MCP-1 plays an important role in the pathogenic mechanisms leading to sepsis.[ MCP-1 also regulated inflammatory progression and the production of pro-inflammatory cytokines.[ Several studies have demonstrated that levels of MCP-1 was markedly increased in sepsis and contributed to systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS).[ In addition, MCP-1 was positive correlate to sepsis severity and can accurately predict the prognosis of sepsis.[ Thus, a high level of MCP-1 maybe be associate with poor prognosis in critically ill patients. Although the ISS and IL-6 score are generally considered to be good biomarkers of trauma prognosis, we demonstrated that combining the MCP-1 level and ISS had the best predictive value. In trauma patients, IL-6 release has been shown to be related to the severity of trauma and complications.[ Our study demonstrated that MCP-1 was superior to IL-6 in judging the prognosis in the early stage of trauma. Katherine et al. reported that antibody neutralization of MCP-1 in a septic mouse model leads to markedly decreased release of IL-1α, IL-1β, and IL-6.[ We also found that MCP-1 was correlated with severity of trauma and pro-inflammatory cytokine IL-6. PCT and CPR are sensitive biomarkers of inflammation. Similar to the previous study,[ we did not find differences in PCT and CRP levels between sepsis and non-sepsis groups. It may be that PCT and CRP act as inflammatory biomarkers, but cannot reflect the injury severity or predict sepsis in trauma patients. In addition, we found that the plasma MCP-1 level was significantly related with the development of sepsis and a potential biomarker to predict development of sepsis. Recently, accumulating evidences demonstrated that MCP-1 genetic variations within the regulatory regions could make patients susceptible to certain inflammation-related diseases, infection and sepsis by altering MCP-1 expression levels.[ Furthermore, a number of studies demonstrated that inhibition or specific antagonism of MCP-1 could decrease the septic response and are beneficial to survival in mouse models of sepsis.[ These results confirmed that MCP-1 played an important role in the pathomechanisms of immune dysregulation and maybe a promising potential therapeutic target for correcting the immune disorder of severe trauma. There are still some limitations in our study. Firstly, the numbers of patients and controls were relatively small, and the data were collected at a single institution. In addition, sepsis and death could be a cause rather than a consequence of higher substrate levels. Furthermore, there were difficulties in obtaining enough blood samples from these patients, which hindered our investigation into the kinetics of plasma MCP-1 levels in long period.

Conclusions

Our study demonstrated that plasma MCP-1 levels were significantly increased in patients with serve trauma. Furthermore, the early plasma MCP-1 was significantly correlated with the severity and development of sepsis in severe trauma patients. Meanwhile, our study revealed that early plasma MCP-1 can improve the performance of ISS to predict sepsis after trauma. In short, our study indicated that MCP-1 might play an important role in the pathogenesis of sepsis after trauma. Further studies are needed to determine whether MCP-1 intervention could prevent the development of poor outcome in patients with severe trauma.

Author contributions

Design: Xiangjun Bai Interpretation: Xiangjun Bai. Research: Yuchang Wang, Qinxin Liu, Xinghua Liu, Xi’e Xu, Tao Liu Data collection: Yuchang Wang, Qinxin Liu, Xinghua Liu, Xi’e Xu, Tao Liu Data Analysis: Yuchang Wang, Qiang Zheng, Wei Gao Cytokines Test: Yuchang Wang, Qiang Zheng, Wei Gao Supervision: Zhanfei Li Drafting: Xiangjun Bai, Zhanfei Li

Acknowledgments

The authors thank all the doctors, nurses, and patients for their dedication in the study. We also thank the medical ethics committee of Tongji Hospital at the Tongji Medical College of Huazhong University of Science and Technology.
  37 in total

1.  Wilderness Medical Society practice guidelines for basic wound management in the austere environment.

Authors:  Robert H Quinn; Ian Wedmore; Eric Johnson; Arthur Islas; Anne Anglim; Ken Zafren; Cindy Bitter; Vicki Mazzorana
Journal:  Wilderness Environ Med       Date:  2014-06-13       Impact factor: 1.518

2.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1.

Authors:  L Gu; S Tseng; R M Horner; C Tam; M Loda; B J Rollins
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

3.  Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study.

Authors:  Robert Kraft; David N Herndon; Celeste C Finnerty; Robert A Cox; Juquan Song; Marc G Jeschke
Journal:  Shock       Date:  2015-03       Impact factor: 3.454

4.  Novel chemokine responsiveness and mobilization of neutrophils during sepsis.

Authors:  Cecilia L Speyer; Hongwei Gao; Nicholas J Rancilio; Thomas A Neff; Gary B Huffnagle; J Vidya Sarma; Peter A Ward
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

5.  Role of MCP-1 in endotoxemia and sepsis.

Authors:  Raina Devi Ramnath; Siaw Wei Ng; Angelo Guglielmotti; Madhav Bhatia
Journal:  Int Immunopharmacol       Date:  2008-03-18       Impact factor: 4.932

6.  Endogenous MCP-1 influences systemic cytokine balance in a murine model of acute septic peritonitis.

Authors:  A Matsukawa; C M Hogaboam; N W Lukacs; P M Lincoln; R M Strieter; S L Kunkel
Journal:  Exp Mol Pathol       Date:  2000-04       Impact factor: 3.362

7.  CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice.

Authors:  Yasuhiro Tsuda; Hitoshi Takahashi; Makiko Kobayashi; Toshiaki Hanafusa; David N Herndon; Fujio Suzuki
Journal:  J Leukoc Biol       Date:  2004-05-03       Impact factor: 4.962

8.  Epidemiology of trauma deaths: a reassessment.

Authors:  A Sauaia; F A Moore; E E Moore; K S Moser; R Brennan; R A Read; P T Pons
Journal:  J Trauma       Date:  1995-02

9.  Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.

Authors:  L Izikson; R S Klein; I F Charo; H L Weiner; A D Luster
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  Monocyte chemotactic protein-1 (MCP-1) in patients with chronic schistosomiasis mansoni: evidences of subclinical renal inflammation.

Authors:  Ana Lúcia P Hanemann; Alexandre B Libório; Elizabeth F Daher; Alice Maria C Martins; Marta Cristhiany C Pinheiro; Mariana S Sousa; Fernando Schemelzer M Bezerra
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more
  10 in total

1.  Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype.

Authors:  Holly A Richendrfer; Mitchell M Levy; Khaled A Elsaid; Tannin A Schmidt; Ling Zhang; Ralph Cabezas; Gregory D Jay
Journal:  Crit Care Explor       Date:  2020-06-10

Review 2.  Unlocking the Untapped Potential of Endothelial Kinase and Phosphatase Involvement in Sepsis for Drug Treatment Design.

Authors:  Matthijs Luxen; Matijs van Meurs; Grietje Molema
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

3.  Herpes Virus Entry Mediator (HVEM): A Novel Potential Mediator of Trauma-Induced Immunosuppression.

Authors:  Michelle E Wakeley; Nicholas J Shubin; Sean F Monaghan; Chyna C Gray; Alfred Ayala; Daithi S Heffernan
Journal:  J Surg Res       Date:  2019-09-12       Impact factor: 2.192

4.  Is all plasma created equal? A pilot study of the effect of interdonor variability.

Authors:  Amanda M Chipman; Shibani Pati; Daniel Potter; Feng Wu; Maximillian Lin; Rosemary A Kozar
Journal:  J Trauma Acute Care Surg       Date:  2020-01       Impact factor: 3.697

5.  Plasma PTX3, MCP1 and Ang2 are early biomarkers to evaluate the severity of sepsis and septic shock.

Authors:  Rui Tian; Xiaoli Wang; Tingting Pan; Ranran Li; Jiahui Wang; Zhaojun Liu; Erzhen Chen; Enqiang Mao; Ruoming Tan; Yang Chen; Jialin Liu; Hongping Qu
Journal:  Scand J Immunol       Date:  2019-10-07       Impact factor: 3.487

6.  Effect of Anti-Inflammatory and Antimicrobial Cosupplementations on Sepsis Prevention in Critically Ill Trauma Patients at High Risk for Sepsis.

Authors:  Noha A Kamel; Moetaza M Soliman; Maha A Abo-Zeid; Mona I Shaaban
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

7.  Lactobacillus rhamnosus GG as dietary supplement improved survival from lipopolysaccharides-induced sepsis in mice.

Authors:  Ko-Chung Tsui; Ting-Lin Yen; Chi-Jung Huang; Kun-Jing Hong
Journal:  Food Sci Nutr       Date:  2021-10-15       Impact factor: 2.863

8.  Cellular distribution of C-C motif chemokine ligand 2 like immunoreactivities in frontal cortex and corpus callosum of normal and lipopolysaccharide treated animal.

Authors:  Xue Shi; Xinrui Gong; Huangui Xiong; Jingdong Zhang
Journal:  BMC Neurosci       Date:  2022-03-30       Impact factor: 3.288

9.  Elevated type I interferon responses potentiate metabolic dysfunction, inflammation, and accelerated aging in mtDNA mutator mice.

Authors:  Yuanjiu Lei; Camila Guerra Martinez; Sylvia Torres-Odio; Samantha L Bell; Christine E Birdwell; Joshua D Bryant; Carl W Tong; Robert O Watson; Laura Ciaccia West; A Phillip West
Journal:  Sci Adv       Date:  2021-05-26       Impact factor: 14.136

Review 10.  Novel Diagnostics and Therapeutics in Sepsis.

Authors:  Kieran Leong; Bhavita Gaglani; Ashish K Khanna; Michael T McCurdy
Journal:  Biomedicines       Date:  2021-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.